Jaguar Health (JAGX) Proxy filing summary

Executive summary

• Special Meeting scheduled for November 6, 2026, to vote on six key proposals impacting capital structure, compensation, and governance.

• Proposals include share issuances, warrant repricing, stock plan amendments, a reverse stock split, ELOC agreement amendment, and potential adjournment.

• Board recommends voting in favor of all proposals to enhance flexibility for capital raising and strategic alternatives.

• Forward-looking statements highlight risks related to capital needs, stock price volatility, and strategic transactions.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock upon exchange of Series Q Preferred Stock and CVP Debt, potentially resulting in CVP affiliates holding a majority stake.

• Proposal 2: Reprice investor warrants to $1.00 per share, enabling exercise and issuance of up to 49,690 shares, with potential dilution.

• Proposal 3: Amend 2014 Stock Incentive Plan to authorize issuance of up to 14% of fully diluted shares as of September 30, 2026.

• Proposal 4: Grant board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-150 within one year.

• Proposal 5: Amend ELOC Agreement to reduce the Floor Price for share sales below $16.50, increasing capital raising flexibility.

• Proposal 6: Approve adjournment of the meeting if more time is needed to solicit proxies.

Board of directors and corporate governance

• Board retains discretion to set reverse split ratio and timing, and may abandon the split if not in stockholders' best interests.

• Board unanimously recommends approval of all proposals.

• Stockholder proposals for the 2027 Annual Meeting must be submitted by January 4, 2027, for inclusion.